Federal and state regulators have formally accused Martin Shkreli of violating a lifetime ban from the pharmaceutical industry, alleging he continued trading stocks and influencing companies despite a 2022 court order. The Federal Trade Commission (FTC) and attorneys general from seven states filed a motion on Oct. 13 in the U.S. District Court for the Southern District of New York, requesting a judge hold Shkreli in civil contempt for his alleged actions.
On Oct. 13, the FTC and state attorneys general filed a motion in the U.S. District Court for the Southern District of New York, accusing Shkreli of flagrantly violating a 2022 court order that permanently barred him from the pharmaceutical industry. The regulators allege that since his release from prison in May 2022, Shkreli has publicly traded shares in at least 60 pharmaceutical companies and discussed their businesses and management through YouTube livestreams, X (formerly Twitter) posts, and Reddit discussions. The motion seeks to compel Shkreli to divest any pharmaceutical stocks he currently owns, pay fines equal to his profits from the trading, and face escalating penalties for future violations, including potential incarceration.
The 2022 court order stemmed from a separate civil antitrust case in which Shkreli was found to have orchestrated a scheme to block lower-cost generic competition for the drug Daraprim. As part of that case, a judge ordered Shkreli to surrender $64.6 million in profits and imposed the lifetime ban on his involvement in the pharmaceutical industry. The ban explicitly prohibits him from owning stakes in pharmaceutical companies or influencing their management or business decisions. This civil case is distinct from Shkreli’s 2017 securities-fraud conviction, for which he served more than four years in prison before his release in May 2022.
Regulators allege that Shkreli repeatedly violated the ban shortly after his release. They cite his YouTube livestreams, where he has publicly traded pharmaceutical stocks since July 2022, as evidence of his ongoing involvement. One example includes a trading challenge announced in June 2023, during which Shkreli discussed his stock trades and provided commentary on pharmaceutical companies. The FTC and state attorneys general argue that his actions demonstrate a clear disregard for the court’s order and seek immediate consequences to enforce compliance.
The FTC’s Bureau of Competition Director, Daniel Guarnera, stated in a press release that the agency would not hesitate to enforce violations of court orders. The motion also requests that Shkreli face financial penalties and potential imprisonment if further violations occur. FTC Commissioner Mark Meador emphasized that a lifetime industry ban is only effective if breaches are met with commensurate consequences.
Shkreli’s legal team has not yet publicly responded to the contempt motion. His representatives have previously argued that his public commentary and stock trading do not constitute a violation of the ban, as they claim his actions were not intended to influence pharmaceutical companies’ operations. However, regulators maintain that his public discussions of company management and stock trades directly contravene the court’s restrictions.
The case highlights ongoing debates about enforcement of lifetime bans in white-collar crime and the boundaries of permissible public commentary for individuals barred from specific industries. Legal experts note that the outcome of this contempt motion could set a precedent for how similar cases are handled in the future, particularly regarding the scope of restrictions and the definition of prohibited activities.